Liraglutide: Uses, Mechanism, and Side Effects

Overview

Managing blood sugar with type 2 diabetes often means adding a second or third medication once diet and exercise plateau. Liraglutide is one such option, a daily injectable that mimics a natural gut hormone to help regulate glucose.

Key Takeaways

• Liraglutide is a GLP-1 receptor agonist approved as an adjunct to diet and exercise for type 2 diabetes.
• It is approved for adults and pediatric patients aged 10 years and older.
• The label carries a boxed warning.
• More than 540 clinical trials have studied liraglutide or involved it as a comparator.
• FAERS reports are dominated by gastrointestinal effects, led by nausea, vomiting, and diarrhoea.

What Liraglutide Is

Liraglutide is a GLP-1 receptor agonist, meaning it closely resembles a hormone the body naturally releases after eating. It shares 97% of its amino acid sequence with human GLP-1. By activating the GLP-1 receptor on pancreatic beta cells, it raises intracellular cyclic AMP, which in turn prompts the pancreas to release more insulin. This mechanism helps lower blood sugar in response to meals.

What Liraglutide Is Approved For

Liraglutide injection is approved as an adjunct to diet and exercise to improve glycemic control in adults and in pediatric patients aged 10 years and older with type 2 diabetes mellitus. It is sold under the brand name Liraglutide. The label advises against combining it with other liraglutide-containing products, since they share the same active ingredient. The product's label carries a boxed warning, so patients and prescribers are directed to review that information carefully before use.

What the Evidence Shows

Liraglutide has been the subject of more than 540 registered clinical trials. Sampled studies include a Phase 2 trial examining incretin-based therapy alongside SGLT2 inhibition in congestive heart failure, and a completed trial that looked at type 2 diabetes outcomes in patients also exposed to pravastatin and paroxetine. Not every study has reached completion; one trial exploring liraglutide in low-responders after bariatric surgery was withdrawn.

Reported Side Effects

FAERS data reflect voluntarily submitted reports, not confirmed incidence or causation. Within that context, the most frequently reported reactions with liraglutide are gastrointestinal: nausea (7,250 reports), vomiting (3,558), and diarrhoea (3,428). Metabolic signals also appear often, including increased blood glucose (4,080 reports), decreased appetite (2,150), and weight decreased (2,148). Pancreatitis (2,355 reports) and headache (2,042) round out the most commonly reported terms.